Innovation Pharmaceuticals Inc (IPIX)

[farrell90]

I hope you are right. I would be delighted if the Brilacidin for Covid 19 results are so positive it would get an immediate pass to an EUA.

Pfizer on the other hand may be hesitant to submit another drug for an early EUA after Merck's experience.

Merck partnered with Oncoimmune for their graft vs host drug for Covid 19 and surprisingly got rejected. Then,in spite of a good Covid 19 anti-inflammatory study; they pulled the drug.

Then you couple that with Cytodyn's experience it appears the FDA is becoming less welcoming.

GLTA,

Farrell

https://www.fiercebiotech.com/biotech/fda-tells-merck-told-to-show-more-data-for-its-oncoimmune-covid-drug-as-eua-pushed-back

https://www.merck.com/news/merck-to-discontinue-development-of-mk-7110-for-covid-19/

https://www.biospace.com/article/releases/oncoimmune-s-saccovid-cd24fc-exhibits-superb-therapeutic-efficacy-a-potential-breakthrough-in-treating-severe-and-critical-covid-19/